Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
about
The use of lorcaserin in the management of obesity: a critical appraisalLorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditureMechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulationObesity pharmacotherapy: current perspectives and future directionsStructural Basis for Molecular Recognition at Serotonin ReceptorsConformational analysis of the anti-obesity drug lorcaserin in water: how to take advantage of long-range residual dipolar couplings.Effects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model.Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversificationHigh-fat and obesogenic diets: current and future strategies to fight obesity and diabetes.Directed evolution of RebH for site-selective halogenation of large biologically active molecules.Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.The use of serotonergic drugs to treat obesity--is there any hope?Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.The utility of animal models to evaluate novel anti-obesity agents.We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse controlActivation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated miceDirectly Observable Behavioral Effects of Lorcaserin in RatsLorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.Lorcaserin for the treatment of obesityLorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.New therapeutic potential for psychoactive natural products.5-HT2C receptor modulators: a patent survey.Approaches to the pharmacological treatment of obesity.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.The safety and efficacy of lorcaserin in the management of obesity.Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial.Safety and tolerability review of lorcaserin in clinical trials.Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue.Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.Lorcaserin for the treatment of obesity? A closer look at its side effects.Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist.Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating.Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.
P2860
Q24594774-1D1FC8B5-92F5-42AD-95BA-27DA2B288D1EQ24611940-C059B655-755E-4B4B-928D-05B75DDC9F75Q26749523-54F92142-6FF5-4B2C-ABBF-AC97A6133115Q26828559-E6B7782E-198B-483B-9D07-75E5C9D2409BQ27676926-0218026B-F447-4EE0-9977-40CE3A7F2A90Q30672639-8E8910A2-8A4E-4071-ADF6-75043355FD6FQ33838889-B3193D90-476F-4A2D-96E3-554D696B1CC2Q34207033-A93DD122-1118-40B4-8DA5-4DEFD14E9838Q34212924-29FE7CF9-CD64-4D58-A466-B564E27403EEQ34462524-23D91279-8BBE-4966-A6A1-B79C7E65D8E4Q34659424-E48E5735-33B6-43E3-952B-18E984D25B41Q34712327-F7FAC358-313D-4BD2-B5C7-BF6A77C69CF1Q34962263-A82635B8-7461-4072-9DF7-F8114E7437A7Q35049574-4A3B1C03-8C76-4497-BAE1-A7FFC19FA1F0Q35188133-3785F3ED-C31B-4E72-AFCE-003E5698C682Q35589958-AF2A8C23-6172-4EFE-9026-AAFCB432EB3EQ35823591-5E0B3EDE-0374-4D30-A724-0D42BAE031AFQ35837700-620BAF45-8B4F-4EC0-8F57-D568E546A88FQ36244665-7AF837ED-549E-42E6-AA29-DC7782AF558DQ36316458-FEAEB0F0-7060-4689-87AD-F4F52B8E935CQ36432310-183ED415-4434-4DA0-A636-C8C285E7B2B4Q36540945-92728C75-CAB0-48B5-804D-5AB7B36DE736Q36777115-28AD5AC1-F265-4DD6-B38E-82BF4CF70E69Q37172259-E45DD772-E71D-4C9B-968D-4AEE09703A83Q37310802-70ECD7AF-91A0-49D0-BF8B-21DAB4E482C9Q37660087-EC7B50DB-6560-4CF5-ADD6-9177E3B965EBQ37789738-B6050F1C-196E-42C6-9D7E-84E35B152205Q37960073-C2BA7D53-46AE-4D9B-BF80-6896EE1A1F82Q38031743-11335AD4-5AB7-43E6-80B2-156D1E798027Q38160636-811B2033-3318-4F53-856D-FBEACD63D780Q38385068-D1EBF119-BAEE-408F-B8C4-297F220E3E9CQ38954263-564E526D-6547-48A3-84CE-C9C9A1BEEE0BQ39298178-96114396-FE00-4FC9-9737-8738A898C2A2Q39768889-E330647A-0A01-4B08-A5C7-AF6171BC5101Q41910031-75DB932A-04EE-435B-93EE-82B541EBAE05Q42957301-AB1BCCBF-D028-4845-B8BF-52409FA31BA1Q45908028-415E7080-97BF-4592-BE7F-40B754604546Q46213450-25A716AF-E6F7-4509-AE76-5C45AE8C0AE0Q47172455-B4060317-E440-45BB-8EF8-78C030B9D828Q47588598-174D3C22-A98B-452F-A249-608B7CD6BCF1
P2860
Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Discovery and structure-activi ...... for the treatment of obesity.
@ast
Discovery and structure-activi ...... for the treatment of obesity.
@en
Discovery and structure-activi ...... for the treatment of obesity.
@nl
type
label
Discovery and structure-activi ...... for the treatment of obesity.
@ast
Discovery and structure-activi ...... for the treatment of obesity.
@en
Discovery and structure-activi ...... for the treatment of obesity.
@nl
prefLabel
Discovery and structure-activi ...... for the treatment of obesity.
@ast
Discovery and structure-activi ...... for the treatment of obesity.
@en
Discovery and structure-activi ...... for the treatment of obesity.
@nl
P2093
P921
P356
P1476
Discovery and structure-activi ...... for the treatment of obesity.
@en
P2093
Albert Ren
Andrew J Grottick
Brian M Smith
Charlemagne S Gallardo
Charles A Gilson
Christina Bjenning
Dipanjan Sengupta
Douglas M Park
Emily B Prieto
Frederique Menzaghi
P304
P356
10.1021/JM0709034
P407
P50
P577
2007-12-21T00:00:00Z